EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Harnessing ADAR-Mediated Site-Specific RNA Editing in Immune-Related Disease: Prediction and Therapeutic Implications

Shenghui Weng iD, Xinyi Yang, Nannan Yu, Peng-Cheng Wang iD, Sidong Xiong, Hang Ruan iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms25010351 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Shenghui Weng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou 215123, China. Hauptthemen laut MEDLINE: RNA Editing, Immune System Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 203 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Shuang Chuang (Mass Innovation and Entrepreneurship) Talent Program, National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ADAR (Adenosine Deaminases Acting on RNA) proteins are a group of enzymes that play a vital role in RNA editing by converting adenosine to inosine in RNAs. This process is a frequent post-transcriptional event observed in metazoan transcripts. Recent studies indicate widespread dysregulation of ADAR-mediated RNA editing across many immune-related diseases, such as human cancer. We comprehensively review ADARs’ function as pattern recognizers and their capability to contribute to mediating immune-related pathways. We also highlight the potential role of site-specific RNA editing in maintaining homeostasis and its relationship to various diseases, such as human cancers. More importantly, we summarize the latest cutting-edge computational approaches and data resources for predicting and analyzing RNA editing sites. Lastly, we cover the recent advancement in site-directed ADAR editing tool development. This review presents an up-to-date overview of ADAR-mediated RNA editing, how site-specific RNA editing could potentially impact disease pathology, and how they could be harnessed for therapeutic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA EditingImmune System DiseasesAnimalsHumansHydrolasesAdenosineHomeostasisRNA

Stichwörter der Autor:innen

ADARRNA editingcomputational resourcesimmune-related disease

Substanzen

HydrolasesAdenosineRNA

Autor:innen und Institutionen

  • Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou 215123, China.
  • MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou 215123, China.

ORCID-Profile: Shenghui Weng, Peng-Cheng Wang, Hang Ruan

Förderung

  • Jiangsu Shuang Chuang (Mass Innovation and Entrepreneurship) Talent Program
  • National Natural Science Foundation of China
  • Priority Academic Program Development of Jiangsu Higher Education Institutions
  • Suzhou Gusu Innovation Leading Talent Program

Zitieren

APA

Weng, S., Yang, X., Yu, N., Wang, P. C., Xiong, S., & Ruan, H. (2023). Harnessing ADAR-Mediated Site-Specific RNA Editing in Immune-Related Disease: Prediction and Therapeutic Implications. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25010351

Vancouver

Weng S, Yang X, Yu N, Wang PC, Xiong S, Ruan H. Harnessing ADAR-Mediated Site-Specific RNA Editing in Immune-Related Disease: Prediction and Therapeutic Implications. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms25010351

BibTeX
@article{Weng2023,
  author = {Weng, Shenghui and Yang, Xinyi and Yu, Nannan and Wang, Peng-Cheng and Xiong, Sidong and Ruan, Hang},
  title = {Harnessing ADAR-Mediated Site-Specific RNA Editing in Immune-Related Disease: Prediction and Therapeutic Implications},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms25010351}
}
Kostenlos starten →